A case of erythrodermic psoriasis with latent tuberculosis infection and hepatitis B cirrhosis treated with Secukinumab and literature review
Due to the selective immunosuppressive effect of biological agents,long-term use in psoriasis patients may lead to reactivation of hepatitis B virus and mycobacterium tuberculosis.Clinical applications have found that Secukinumab is safer than other biological agents.This article retrospectively collected a case of erythrodermic psoriasis patient with latent tuberculosis infection and hepatitis B cirrhosis treated by Secukinumab,who suffered from bilateral femoral head necrosis due to irregular systematic use of hormones.After informed consent,the patient was given anti-hepatitis B virus and pre-ventive antituberculosis treatment.After that,the patient was given the standard protocol of Secukinumab and then bilateral total hip arthroplasty.At the 24th week of treatment,the patient's psoriasis area and severity index(PASI)reached 90;and at the 40th week,the patient reached PASI100,at the 60th week of treatment,the patient still reached PSAI90,with only the scaly erythema scattered in front of both tibia.Up to now,no hepatitis B virus replication and active tuberculosis have been found during follow-up.Through the introduction of this case and review of relevant literature,this article shows the effec-tiveness and safety of Secukinumab,and promote dermatologists'awareness of biological agents in improvement of metabolic comorbidity,hoping to make more patients with psoriasis accompanied by hepatitis B and tuberculosis obtain better clinical prognosis.
Erythrodermic psoriasisLatent tuberculosis infectionHepatitis B cirrhosisSecukinumabAnti inter-leukin-17A
国家科技期刊平台
NSTL
万方数据
维普
